Journal of Alzheimer's Disease

World Brain Mapping Foundation (WBMF) announced its 2024 award recipients holding its 21st Gathering for Cure (GFC) Awards Gala at the Historic Millenium Biltmore hotel in LA.

Retrieved on: 
Tuesday, March 12, 2024
Karma, Research, Brain mapping, Culture, Brain technology, Innovation Park, Taste, Veteran, WBMF, Doe, Patient, Millennium Biltmore Hotel, Alzheimer's disease, Neuroscience, Disease, Associate, Journal, Loma Linda University, GFC, Health, Pioneer, Michelson Medical Research Foundation, Journal of Alzheimer's Disease, NASA, Neuroelectrics, DSM-IV codes, Therapy, DRS, Springer Nature, State, Neurosurgery, Pharmaceutical industry

LOS ANGELES, March 11, 2024 /PRNewswire/ -- The World Brain Mapping Foundation (WBMF) announced its 2024 award recipients and will hold the 21st Gathering for Cure (GFC) Awards Gala on Friday March 15, 2024 at former home to the Oscars, Millennium Biltmore Hotel in Los Angeles.

Key Points: 
  • LOS ANGELES, March 11, 2024 /PRNewswire/ -- The World Brain Mapping Foundation (WBMF) announced its 2024 award recipients and will hold the 21st Gathering for Cure (GFC) Awards Gala on Friday March 15, 2024 at former home to the Oscars, Millennium Biltmore Hotel in Los Angeles.
  • Joe Bolanos, Kevin Morris, George Perry, Dave Baron, and Ms. Ira Soebroto-Bullo (Golden Axon Leadership award) and Aysha Noor and Jemma Yoo (Student Service, Research and Leadership Award).
  • "Our award recipients are truly pioneers in their fields who have impacted millions of patients globally", said Dr. Babak Kateb, President of WBMF.
  • "GFC award is also aimed at raising funds for introducing new diagnostics and therapeutics for neurological disorders."

Deputy Minister of Ukraine, Nataliia Kalmykova, will be speaking at the LA Convention Center this week

Retrieved on: 
Tuesday, March 12, 2024
Karma, SBMT, Brain, Congress, Brain mapping, Neuroscience, Neurology, Multiple sclerosis, Alzheimer's disease, Ophthalmology, Doe, Knowledge, Los Angeles Convention Center, Associate, Journal, Loma Linda University, Disease, Military medicine, World Congress, AI, Cadaver, Neuro-oncology, Society, Michelson Medical Research Foundation, Journal of Alzheimer's Disease, NASA, Neuroelectrics, Regenerative medicine, Therapy, Spine, Multimedia, Springer Nature, B cell, Neurosurgery

Deputy Minister of Ukraine, Nataliia Kalmykova, will be amongst keynotes ; Ukrainian neurosurgeons from the frontline will also be speaking about combat casualty care and participate in the convention in person.

Key Points: 
  • Deputy Minister of Ukraine, Nataliia Kalmykova, will be amongst keynotes ; Ukrainian neurosurgeons from the frontline will also be speaking about combat casualty care and participate in the convention in person.
  • Since the beginning of the war in Ukraine, SBMT has been supporting Ukrainian doctors with training and medical equipment.
  • The SBMT World Congress is renowned for its comprehensive program, offering a diverse range of presentations, hands-on workshops, Bioskills cadaver labs, and an expansive exhibition hall.
  • Attendees can expect to engage with cutting-edge research, innovative technologies, and expert insights that are shaping the future of neurosciences and neurotechnology.

Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease

Retrieved on: 
Monday, December 11, 2023
Technology, Medical Devices, Neurology, Science, Consumer, Clinical Trials, Biotechnology, Health, Other Science, Research, Other Technology, Software, Other Health, Hardware, Pharmaceutical, Data Management, Seniors, Axon, Therapy, Alzheimer's disease, HOPE, White, Hippocampus, Disease, Clinical trial, Journal of Alzheimer's Disease, Learning, White matter, Patient, Journal, FDA, Atrophy, Memory, MRI, Cognito, HIV disease progression rates, Medical imaging

Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging data from its Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease .

Key Points: 
  • Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging data from its Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease .
  • White matter volume assessments were performed using T1-weighted MRI, and myelin content assessments were performed using T1-weighted/T2-weighted MRI ratios.
  • “Our Phase 2 OVERTURE study imaging results published in the Journal of Alzheimer's Disease, show that our proprietary gamma sensory stimulation reduced white matter atrophy and preserved brain myelin content in patients.
  • The Company’s lead therapy is currently in a pivotal study (HOPE) in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation.

Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus

Retrieved on: 
Monday, September 13, 2021
Patient, Risk, Diabetes, Conditional sentence, Intention, Vaccine, Dementia, Department, BET, Bromodomain, Disease, ALP, Alkaline phosphatase, Government budget balance, Peripheral artery disease, Gene expression, Fabry disease, COVID-19, Montreal, Virus, GLOBE, Journal of Alzheimer's Disease, Cognition, End organ damage, Alzheimer's disease, Standard of care, Food, Cell, FDA, University of Nevada, Reno, Breakthrough therapy, Safety, Cardiovascular disease, Chronic kidney disease, Nature, TSX, HERE, LINK, US Foods, University, SEDAR, CVD, Company, Clinical trial, Legislation, COVID, Population, Journal, News, Pharmaceutical industry, Medical device

CALGARY, Alberta, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), a world leader in epigenetics, or gene regulation, announces today new data that demonstrates their first-in-class oral small molecule BET inhibitor candidate Apabetalone significantly improves cognition and reduces cognitive decline among high-risk patients with cardiovascular disease (CVD) and diabetes mellitus.

Key Points: 
  • These findings suggest that the BET inhibitor Apabetalone holds promise as a safe and effective therapeutic avenue for vascular cognitive impairment.
  • These findings are a sub-study of the previously published BETonMACE cardiovascular disease (CVD) outcome study.
  • This analysis highlights the continuing unmet need for treatment options for vascular cognitive impairment in high-risk cardiovascular patients with diabetes.
  • Risk of vascular cognitive impairment increases with age, cardiovascular disease (CVD), diabetes, and chronic kidney disease.

New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression

Retrieved on: 
Tuesday, October 27, 2020
Medical specialties, Branches of biology, Clinical medicine, Vaccination, Vaccine, Virology, Alzheimer's disease, Journal of Alzheimer's Disease

The long-term follow-up result to the vaccine responders demonstrated positive benefit from the vaccine, indicating that vaccine against Alzheimers disease with A is promising if the treatment can overcome the adverse effects.

Key Points: 
  • The long-term follow-up result to the vaccine responders demonstrated positive benefit from the vaccine, indicating that vaccine against Alzheimers disease with A is promising if the treatment can overcome the adverse effects.
  • Testing of this new vaccine was conducted on mice genetically engineered to develop high levels of A and behavioral/cognitive abnormalities that mimic human Alzheimers disease, also known as transgenic1 mice.
  • The Journal of Alzheimers Disease ( http://www.j-alz.com ) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimers disease.
  • Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes.

DPW Holdings’ Announces that the Journal of Alzheimer’s Disease Highlights Milestone Research (AL002) Licensed by Alzamend Neuro® from the University of South Florida

Retrieved on: 
Tuesday, October 27, 2020
S&P/TSX 60 Index, Thomson Reuters, Journal of Alzheimer's Disease, Companies, Mass media, Publications

DPW has an investment in Alzamend Neuro (Alzamend) through its subsidiary, Digital Power Lending, LLC.

Key Points: 
  • DPW has an investment in Alzamend Neuro (Alzamend) through its subsidiary, Digital Power Lending, LLC.
  • Alzheimers disease affects more than 5.8 million Americans at an estimated cost of over $305 billion in 2020, according to the Alzheimers Association.
  • Alzamend Neuro, Inc., (Alzamend) ( www.Alzamend.com ) is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California.
  • The Journal of Alzheimer's Disease has an Impact Factor of 5.101 according to Thomson Reuters' 2008 Journal Citation Reports.